These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28552612)

  • 1. Efficacy and safety of incretin-based drugs in patients with type 1 diabetes mellitus: A systematic review and meta-analysis.
    Wang W; Gao Y; Chen D; Wang C; Feng X; Ran X
    Diabetes Res Clin Pract; 2017 Jul; 129():213-223. PubMed ID: 28552612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
    Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
    Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression.
    Musso G; Sircana A; Saba F; Cassader M; Gambino R
    PLoS Med; 2020 Dec; 17(12):e1003461. PubMed ID: 33373368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
    Amori RE; Lau J; Pittas AG
    JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
    Wu S; Cipriani A; Yang Z; Yang J; Cai T; Xu Y; Quan X; Zhang Y; Chai S; Sun F; Zhan S
    Expert Opin Drug Saf; 2018 Mar; 17(3):243-249. PubMed ID: 29320889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of metformin for patients with type 1 diabetes mellitus: a meta-analysis.
    Liu C; Wu D; Zheng X; Li P; Li L
    Diabetes Technol Ther; 2015 Feb; 17(2):142-8. PubMed ID: 25369141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Stem Cell Therapy for T1DM: An Updated Systematic Review and Meta-Analysis.
    Sun SY; Gao Y; Liu GJ; Li YK; Gao W; Ran XW
    J Diabetes Res; 2020; 2020():5740923. PubMed ID: 33102605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.
    Chai S; Yu S; Yang Z; Wu S; Gao L; Wang H; Zhang Y; Zhan S; Ji L; Sun F
    BMJ Open Diabetes Res Care; 2019; 7(1):e000728. PubMed ID: 31641525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect and Safety of Adding Metformin to Insulin Therapy in Treating Adolescents With Type 1 Diabetes Mellitus: An Updated Meta-Analysis of 10 Randomized Controlled Trials.
    Liu Y; Chen H; Li H; Li L; Wu J; Li H
    Front Endocrinol (Lausanne); 2022; 13():878585. PubMed ID: 35707462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
    Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and patient acceptability of Technosphere inhaled insulin for people with diabetes: a systematic review and meta-analysis.
    Pittas AG; Westcott GP; Balk EM
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):886-94. PubMed ID: 26341170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of incretin-based therapies on β-cell function in type 1 diabetes mellitus: a systematic review and meta-analysis.
    Wu Y; Lu Y; Yang S; Zhang Q
    J Int Med Res; 2021 Dec; 49(12):3000605211066306. PubMed ID: 34939442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An updated review on cancer risk associated with incretin mimetics and enhancers.
    Tseng CH; Lee KY; Tseng FH
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
    Cornell S
    J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
    Drab SR
    Pharmacotherapy; 2010 Jun; 30(6):609-24. PubMed ID: 20500049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
    Neumiller JJ
    Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incretin-based therapies for patients with type 1 diabetes: a meta-analysis.
    Liu L; Shao Z; Xia Y; Qin J; Xiao Y; Zhou Z; Mei Z
    Endocr Connect; 2019 Mar; 8(3):277-288. PubMed ID: 30694794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.